Cargando…

Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence

OBJECTIVES: Healthcare professionals (HCPs) with opioid dependence are at risk for relapse and death, particularly in the first year of recovery; however, maintenance treatment with opioid agonists is controversial in this safety-sensitive group. We evaluated long-term safety, tolerability, and trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Earley, Paul H., Zummo, Jacqueline, Memisoglu, Asli, Silverman, Bernard L., Gastfriend, David R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457834/ https://www.ncbi.nlm.nih.gov/pubmed/28358754 http://dx.doi.org/10.1097/ADM.0000000000000302

Ejemplares similares

Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
por: Nunes, Edward V., et al.
Publicado: (2015)

Whose mu fared better? The effect of extended-release naltrexone (XR-NTX) on treatment outcomes for opioid and alcohol users
por: Crèvecoeur-MacPhail, Desirée A
Publicado: (2015)

The Need for Psychosocial Interventions to Facilitate the Transition to Extended-Release Naltrexone (XR-NTX) Treatment for Opioid Dependence: A Concise Review of the Literature
por: Ramsey, Susan E., et al.
Publicado: (2016)

Adaptation of a standard extended-release naltrexone (XR-NTX) protocol for rural re-entering offenders with OUD
por: Staton, Michele, et al.
Publicado: (2021)

Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)
por: Kunøe, Nikolaj, et al.
Publicado: (2016)

Naltrexone extended-release injection: an option for the management of opioid abuse
por: Taylor, Robert, et al.
Publicado: (2011)

Venlafaxine extended release (XR) in the treatment of panic disorder
por: Kjernisted, Kevin, et al.
Publicado: (2007)

Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures
por: Neutel, Joel M., et al.
Publicado: (2013)

Medication Treatment for Opioid Use Disorders:: A Brief Overview with Comments on Extended Release Naltrexone
por: Woody, George
Publicado: (2017)

Personal recovery among people with opioid use disorder during treatment with extended-release naltrexone
por: Marciuch, Anne, et al.
Publicado: (2023)

Factors associated with willingness to take extended release naltrexone among injection drug users
por: Ahamad, Keith, et al.
Publicado: (2015)

The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV
por: Parchinski, Kaley, et al.
Publicado: (2023)

Comment on “Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence”
por: Silverman, Bernard, et al.
Publicado: (2018)

Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended‐Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens
por: Comer, Sandra D., et al.
Publicado: (2020)

Long-Acting Injectable Naltrexone for the Management of Patients with Opioid Dependence
por: Kjome, Kimberly L., et al.
Publicado: (2011)

Epidemiologic and Molecular Pathophysiology of Chronic Opioid Dependence and the Place of Naltrexone Extended-Release Formulations in its Clinical Management
por: Reece, Albert Stuart
Publicado: (2012)

Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018
por: Jain, Priya, et al.
Publicado: (2020)

Impact of Impulsivity, Hyperactivity, and Inattention on Discontinuation Rate among Opioid-Dependent Patients Treated with Extended-Release Naltrexone
por: Karlsson, Ann Tarja, et al.
Publicado: (2022)

Association between body mass index and treatment completion in extended-release naltrexone-treated patients with opioid dependence
por: Li, Xinyi, et al.
Publicado: (2023)

A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder
por: Wang, Gang, et al.
Publicado: (2014)

Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis
por: Hoffman, Kim A., et al.
Publicado: (2021)

Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence
por: Wang, A-L, et al.
Publicado: (2015)

Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
por: Velasquez, Melissa, et al.
Publicado: (2019)

Naltrexone Implant for Opioid Use Disorder
por: Edinoff, Amber N., et al.
Publicado: (2021)

Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended‐release naltrexone in a residential setting
por: Mannelli, Paolo, et al.
Publicado: (2022)

Open Label Trial of Naltrexone Implants: Measuring Blood Serum Levels of Naltrexone
por: Colquhoun, Ross M.
Publicado: (2013)

Levels of Impulsivity, Hyperactivity, and Inattention and the Association with Mental Health and Substance Use Severity in Opioid-Dependent Patients Seeking Treatment with Extended-Release Naltrexone
por: Karlsson, Ann Tarja, et al.
Publicado: (2021)

Patients’ experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study
por: Marciuch, Anne, et al.
Publicado: (2022)

Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users
por: Setnik, Beatrice, et al.
Publicado: (2017)

Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials
por: Murphy, Sean M., et al.
Publicado: (2020)

The Vivitrol pilot program (VPP): initial quantitative findings from an extended-release naltrexone study
por: Rieckmann, Traci, et al.
Publicado: (2015)

Naltrexone/Bupropion extended release‐induced weight loss is independent of nausea in subjects without diabetes
por: Hong, K., et al.
Publicado: (2016)

Effect of Aptensio XR (Methylphenidate HCl Extended-Release) Capsules on Sleep in Children with Attention-Deficit/Hyperactivity Disorder
por: Owens, Judith, et al.
Publicado: (2016)

Long‐term efficacy and safety of adjunctive extended‐release oxcarbazepine (Oxtellar XR(®)) in adults with partial‐onset seizures
por: Chung, S. S., et al.
Publicado: (2015)

Adapting treatment length to opioid‐dependent individuals’ needs and preferences: a 2‐year follow‐up to a 1‐year study of extended‐release naltrexone
por: Solli, Kristin Klemmetsby, et al.
Publicado: (2021)

Development of an Extended-Reality (XR)-Based Intervention to Treat Adolescent Obesity
por: Malik, Neal, et al.
Publicado: (2022)

Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients
por: Zaaijer, Eline R., et al.
Publicado: (2015)

Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic
por: Nguyen, Thuy, et al.
Publicado: (2022)

Pharmacological enhancement of naltrexone treatment for opioid dependence: a review
por: Mannelli, Paolo, et al.
Publicado: (2011)

Anhedonia to music and mu-opioids: Evidence from the administration of naltrexone
por: Mallik, Adiel, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vsfee2bah4sqjpj16p0vijc6sm